Gene Therapy for Tay-Sachs Disease (Phase 1: Natural History Data Gather)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 4
- 试验地点
- 2
- 主要终点
- Biomarkers
研究概览
简要总结
Hypothesis: To study the natural history of Tay-Sachs disease and evaluate therapeutic interventions.
This study is intended to work in collaboration with NCT00668187 "A Natural History Study of Hexosaminidase Deficiency." Because so few patients with Tay-Sachs disease present annually, we will maximize both research projects by enrolling patients in both studies. For this present study, we will perform retrospective medical record review to gather data. Through this medical record review, we will collect biomarker analysis results, neuroimaging report data, quality-of-life questionnaire data and ophthalmology exam findings. If the subject has undergone therapy or treatment, the results will be noted.
详细描述
Much has been done in the past four decades to better understand, improve diagnostic measures of, and prevent hexosaminidase deficiency diseases, yet all of them - Tay-Sachs, Sandhoff, and Late Onset Tay-Sachs (LOTS) - remain diseases without treatment. Much work remains to be done to understand and effectively treat these diseases. To date, no comprehensive assessment of the natural history of Tay-Sachs or Sandhoff has been undertaken. The information that is gathered through this study will characterize and describe the Tay-Sachs disease population as a whole, including the variability and progression of this disease. This information, in turn, will function as a point of reference against which to assess the efficacy of therapeutic interventions. Therapeutic interventions may include any treatments/therapies the subject may have undergone in the past, including hematopoietic cell transplantation, and/or the administration of miglustat, acetylcysteine, or other pharmaceutical agents; and possible future gene therapies.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Any person who has been diagnosed with a hexosaminidase deficiency disease can be included in this study.
排除标准
- •The only exclusion criteria is a desire not to participate in this study.
结局指标
主要结局
Biomarkers
时间窗: Participants will be followed for the duration of the study, an expected average of two years.
Biomarkers data to be collected include: 1. CSF (cerebro-spinal fluid) hexosaminidase A activity 2. CSF GM2-ganglioside 3. CSF protein 4. CSF chitotriosidase
次要结局
- Results of Ancillary Therapies or Treatments(Participants will be followed for the duration of the study, an expected average of two years.)
- Clinical Indicators(Participants will be followed for the duration of the study, an expected average of two years.)